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Growing evidence suggests that the patient’s immune responsemay play amajor role in the long-term efficacy of antibody therapies
of follicular lymphoma (FL). Particular long-lasting recurrence free survivals have been observed after first line, single agent
rituximab or after radioimmunotherapy (RIT). Rituximabmaintenance, furthermore, has amajor efficacy in prolonging recurrence
free survival after chemotherapy.On the other hand, RIT as a single step treatment showed a remarkable capacity to induce complete
and partial remissions when applied in recurrence and as initial treatment of FL or given for consolidation. These clinical results
strongly suggest that RIT combined with rituximab maintenance could stabilize the high percentages of patients with CR and
PR induced by RIT. While the precise mechanisms of the long-term efficacy of these 2 treatments are not elucidated, different
observations suggest that the patient’s T cell immune response could be decisive. With this review, we discuss the potential role of
the patient’s immune system under rituximab and RIT and argue that the T cell immunity might be particularly promoted when
combining the 2 antibody treatments in the early therapy of FL.
1. Long-Term Complete Remissions of
FL Have Been Reported after Either RIT or
Rituximab Treatment
Advanced stage follicular lymphoma (FL) cannot be cured
by standard chemotherapy [1]. In the frequently slow evo-
lution of the disease, FL tends to become less responsive to
chemotherapy, remissions lasting shorter time or the disease
transforms to higher grade lymphoma. In recent years, it has
been shown repeatedly that allogeneic hematopoietic stem
cells transplantation (HSCT) can induce a plateau of tumor
free survival and has a curative potential [2–4], suggesting
that donor T cells bear the potential to cure FL patients [5].
Thefirst, highly efficient anti-CD20 radioimmunotherapy
(RIT) has been published in 1993 [6, 7] and single agent
rituximab (Mabthera, Rituxan, Roche Ltd, Genentech) treat-
ments were published a few years later [8–11]. Long-term
complete remissions (CR) lasting 8 years or more have since
been reported after single agent rituximab as well as after
RIT [9, 10, 12–15].These sustained remissions might be a first
indication of the curative potential of the 2 antibody based
treatments.
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There is increasing evidence that the patient’s T cells
could be particularly involved in these long-term responses,
as recently postulated in a letter to the editor [16]. The
combination of the 2 treatments, as discussed here, with the
particular aim to preserve, stimulate, and study the patient’s
T cell response would appear attractive notably when being
initiated as first line or early treatment of FL.
2. The Patient’s Immune Response
May Be Relevant to Long-Term Tumor
Control of FL
The tumor microenvironment shows remarkable adaptations
in FL [17]. Tumor cells interact with stromal cells allowing
the promotion of tumor growth [18–20]. Cytotoxic T lympho-
cytes were shown to have a tumor controlling potential, but,
once they are present in the tumor microenvironment, they
may be inhibited by regulatory T and/or B cells [21–25] or
exhausted as shown in melanoma [26] and lymphoma [27].
Conversely, immune response signatures have identified
tumor infiltrating T cells, monocytes, and dendritic cells as
being predictive of survival of FL [28]. RT-PCR based gene
expression profiling results were in agreement with these
observations [29]. Interestingly, high numbers of tumor infil-
trating FOXP3 positive regulatory T cells were also predictive
of improved overall survival [30]. The nature as well as the
potential heterogeneity of regulatory T cells remains, how-
ever, controversial [31, 32]. Recently, follicular Th cells in the
tumor microenvironment have also been implicated in pro-
moting immunosuppression [33]. Thus, contradicting roles
have been observed for tumor infiltrating stromal cells [32].
Under rituximab treatment elimination of regulatory B
cells (Breg, B10) could be an explanation for the observation
of favorable T cell responses [24, 34]. Different groups have
also studied at the preclinical and clinical level the efficacy
of blocking T-cell inhibitory receptors [35]. Anti-CTLA-4
[25, 36] and anti-PD-1 [37, 38] treatments showed interesting
results in animals and lymphoma patients. Possibly, this
approach may become increasingly successful, similar to the
progress in patients withmelanoma, lung, and kidney cancers
[39–42].
Allogeneic HSCT provides the patient with the immuno-
logical graft antilymphoma effect that is not necessarily linked
with a graft versus host reactivity [43]. It leads to a plateau in
tumor free survival and provides a chance of cure in advanced
stage FL [2–4]. In nonmyeloablative allogeneic HSCT, the
potential curative response of chemorefractory patients who
had a conditioning regimen including 90Y-ibritumomab,
fludarabine, and cyclophosphamide was interpreted as likely
being related to the graft versus lymphoma effect, facilitated
by an improved initial disease control, provided by radioim-
munotherapy (RIT) [2].
Weiner et al. highlighted 3 potential mechanisms for
induction of a tumor-antigen-specific immune response [44],
namely, antibody dependent cellular cytotoxicity (ADCC),
antibody-targeted cross-presentation of tumor antigens [45],
and triggering of the anti-idiotypic antibodies [44]. Regard-
ing the lattermechanism, the anti-idiotype antibody response
of FL patients after idiotype vaccination was shown to corre-
late with better overall survival [46]. Such a “vaccinal effect”
resulting in the induction of a specific anti-idiotype T cell
response has also been observed after rituximab treatment
[47].
Different preclinical studies further highlighted the pote-
ntial role of rituximab alone or in combination with vaccines
in immune stimulation leading to long-term protection in
lymphoma models [48–50]. Stimulation of CD8 T cells has
been shown to provide long-lasting antitumor immune pro-
tection in syngeneic mouse lymphoma [51–53]. Toll-like
receptor stimulation in combination with rituximab treat-
ment has been explored in first clinical studies [54, 55].
3. Single Agent Rituximab Treatment Is
Able to Stimulate T Cell Responses
Single agent rituximab treatment has been studied in different
trials [8–11]. Rituximab is particularly attractive due to its
capacity to treat B lymphoma while totally sparing T cells
[9]. Rituximab maintenance has been shown to be highly
efficient after the second line R-chemotherapy but is currently
also proposed after the first line R-chemotherapy with a
significant benefit shown in the PRIMA trial [56]. Long-
lasting complete responses (CR) have been observed in FL
patients responding (67%) in an early SAKK trial to initial,
single agent rituximab. 45% of the responding patients after
first line rituximab reached 8 years continued CR when
randomized into the rituximab maintenance arm [9], even
though rituximabmaintenance in this early study consisted of
only 4 supplemental antibody injections administered every
2nd month. Long-term responses were also described after
rituximab standard treatment alone [10].
Upon rituximab treatment of lymphoma, activation of
NK cells occurs [57] and presence of high numbers of CD4
and CD8 T cells has been shown as being favorable [58]. CD4
T helper cells, CD8 T cells, and NK cells remained stable
under rituximab treatment while helper and NK cells were
significantly associated with response and EFS, respectively
[59]. A lymphoma idiotype-specific T cell response was
described for FL patients treated by rituximab alone, sugge-
sting that this therapymight also act as a vaccine [47]. Tumor-
infiltrating T-helper cells are repressed in the tumor envi-
ronment as compared with the same population in normal
lymph nodes, however, it was shown that they retain their
polyfunctional potential to respond to vaccinal stimulation
[60]. These observations clearly indicate that rituximab can
stimulate the patient’s antilymphoma T cell response.
Possibly, another set of T cells, the 𝛾𝛿 T cells may be
involved in FL immunity [61, 62]. Rituximab could poten-
tially play an enhancing role with regard to these cells as
well [63, 64]. Furthermore, under combined treatment with
rituximab and interferon-𝛼 [65], the presence of CD4+ and
CD8+ T cells was shown to be favorable while in a different
study interferonwas able to abrogate the negative effect of IL4
on immune cells [58].
Elimination of regulatory B cells (Breg, B10) could be a
further explanation to the observation of T cell responses
under rituximab treatment [24, 34]. In mice, such Il-10
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producing B10 cells inhibited lymphoma clearance during
anti-CD20 immunotherapy. Stimulation of effector T cells
with a TLR3 agonist was able to overcome the negative
regulatory effects of B10 cells [34]. Since B10 cells are at
least partially eliminated by the anti-CD20 therapy, the B cell
mediated immunesuppression may be abrogated or at least
weakened.
4. Single Agent or Consolidation RIT Induces
Long-Term CR at High Frequency
RIT has been shown to be an effective single agent therapy at
conventional, nonmyeloablative dosing aswell as in high dose
therapy both in patients in relapse [6, 7, 66] and as an initial
treatment [12, 67]. RIT consolidation after chemotherapy was
shown to convert high numbers of partial remissions (PR)
into CR and to provide prolonged progression free survival
[68, 69], the latter being also confirmed at the molecular level
[14, 70]. Regarding the upfront, single agent RIT with 131I-
tositumomab [12], a 40% 10-year relapse free survival was
reported [13]. While anti-CD20 directed RIT also reduced
B cells, T cell responses in these patients appeared to be
preserved [12]. We observed similarly long-lasting CR in a
small series of relapsed indolent lymphoma patients treated
between 1999 and 2001with 131I-tositumomab [71], with 6 out
of 12 patients showing continuedCR at currently 12 years after
RIT [72].
The particular high efficacy of RIT is probably not
explained by the delivered radiation dose or by the 2 injec-
tions of anti-CD20 antibody given at reduced dose. Rather,
the combination of both may be important. Indeed, it has
been shown that irradiation can contribute to the induction
of durable antitumor response inmousemodels of lymphoma
[52, 53]. It seems thus reasonable to hypothesize that the long-
term efficacy of RIT is dependent on the activation and/or the
functional preservation of the patient’s T cell antilymphoma
response [12, 13]. Furthermore, the fact that the two approved
anti-CD20 antibodies, tositumomab, and ibritumomab are
of murine origin implies that the tumor cells are targeted
with murine antigens, which can be recognized in their
processed form by the patient’s T lymphocytes [73] via cross-
presentation by antigen presenting cells, possibly together
with antigens from dying tumor cells [45]. CRs induced by
RIT might liberate the patient’s T cells immunity from the
immunosuppressive state imposed by live tumor masses [26]
and Breg cells [24].
5. The Combination of Two Efficient
Antibody Based Treatments May Limit
Toxicity While the Long-Term Application
(Maintenance) of Rituximab Should Favor
the Development of an Immune Response
Major efforts in cancer treatment are currently directed
into development of immunotherapy. In this respect, one
might consider rituximab treatment as a lucky punch since
rituximab treatment is efficient in patients, has moderate
side effects, and has been shown to activate NK cells [57].
Rituximab can have a vaccination effect inducing anti-
idiotype T cell responses [47], and rituximab treatment alone
is able to lead to long-lasting CR in FL patients [9]. While the
underlying mechanisms of the efficacy of rituximab are not
yet clearly elucidated, itmightwell bemultifunctional beyond
T cells responses.
There are different reasons to combine RIT with rituxi-
mab maintenance. First, long-term results have been des-
cribed for both treatments. Both treatments are of moderate
toxicity and present a favorable potential of immune response
triggering. RIT tumor bulk reduction is known to be highly
efficient and could thus potentially reduce tumor mediated
immunesuppression. RIT in combination with a long-term
treatment, such as rituximab maintenance known to trigger
the immune system, could also have a higher chance to build
up a robust antitumor immune response and lead to longer
recurrence free survival.
We hypothesize that the patient’s T cells would mediate
the long term efficacy of rituximab and RIT. This hypothesis
is only supported by indirect evidence of observations in
patients and preclinical studies. Nevertheless, different stud-
ies have shown that rituximab can stimulate the patient’s T
cells and have a vaccination effect while preclinical studies
have shown that such effects can be decisive for cure in
syngeneic mouse models. In that sense the hypothesis of a
major T cell involvement in antibody treatment of FL joins
other effects of rituximab that is clearly able to elicit direct
apoptosis, ADCC, CDC, or opsonization, although it remains
to be determined which of these mechanisms are decisive
in patients. Regarding RIT, we argue that the radiation
dose given to tumor with nonmyeloablative RIT and the
2 modest amounts of unlabeled antibody are most likely
insufficient to explain its long-term efficacy when given as
monotherapy upfront [13] or in relapse [69] of FL or indolent
lymphoma. These long-term efficacies of RIT and rituximab
in indolent lymphoma, a disease that cannot be cured in
its advanced form by conventional treatment, prompt the
search of different mechanisms of efficacy than the common
ones.
Induction R-chemotherapy such as R-CVP, R-CHOP,
R-MCP, and R-CHVP+I has been studied in large, ran-
domized phase III trials in comparison with chemotherapy
alone and has shown the advantage of adding rituximab
to chemotherapy leading to improved PFS and frequently
also OS [74–77], as recently discussed [78]. Adding 2-year
rituximabmaintenance to such induction therapy was shown
in a large phase III trial to improve PFS [56]. Two recent
phase III trials showed at least a similar efficacy for com-
bined R-bendamustin treatment compared with R-CHOP
[79, 80].
In view of the particular high and reliable efficacy of
adding rituximab to different chemotherapies and further
using it inmaintenance, it is intriguing thatmaintenance trea-
tment with anti-CD20 antibodies has not yet been evaluated
in combinationwith RIT, possibly because RIT and rituximab
are developed with different perspectives. An ongoing phase
II study (NCT00770224) piloted by SWOG investigates the
combined approach of R-CHOP induction chemotherapy
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followed by 131I-tositumomab consolidation and 4-year rit-
uximabmaintenance. First, results of a similar front line study
combining R-CHOP followed by 90Y-radioimmunotherapy
and maintenance rituximab over 2 years showed a sustained
immune response with regard to T cell counts and memory
immune responses while B cells were repressed [81]. A high
number of long-term molecular remissions in FL patients
were reported in that study as well [81].
Radioimmunotherapy in the upfront setting has shown a
remarkable capacity to induce high numbers of long-lasting
CR. While R-CHOP combined with rituximab maintenance
is currently a well-established upfront treatment, the combi-
nation of RIT with rituximab has never been studied. RIT
is frequently seen as an alternative therapy to rituximab
[82, 83]. This is also the case in a new randomized study
that compares rituximab treatment with 131I-tositumomab
therapy in relapsed FL patients (NCT00078598). However,
rituximab treatment is a unique biological treatment with
minor toxicity given under R-chemotherapy and in mainte-
nance [84–87]. Clearly, RIT as a single step therapy involves
a different therapeutic mechanism than rituximab mainte-
nance. Furthermore, RIT presents the unique capacity of
inducing high numbers of CR and of converting PR into CR
when used in consolidation. This induction of CR notably
may be important for the recovery of an effective T cell
response since large tumors are able to inhibit the functioning
of T cells [88–91].
Different studies have shown that therapeutic options
for FL remain open after RIT, including as well collection
and transplantation of HSCT [92]. Furthermore, large studies
have shown that MDS incidence is not increased after RIT
[93, 94] but might rather be related to combination with
preceding chemotherapies, particularly when these include
fludarabine [95, 96].
Based on the hypothesis that a preserved or stimulated
T cell response mediates long-term CR of FL, we argue that
the unique capacity of RIT of inducing high numbers of
long-lasting CR by its own, particularly when used upfront
[12, 13], would merit to be evaluated in combination with
maintenance by rituximab or another anti-CD20 antibody
[97–99], possibly double antibody treatment [100, 101] or
with adjunction of interferon-𝛼 [65]. Such combinationsmay
have only moderate toxicity for the patient himself and his
T cells and may be most beneficial in previously untreated
patients.
Further insight should be obtained by direct monitoring
of the patient’s lymphoma specific T cells in RIT studies
combined with rituximab maintenance. In parallel, other
components of the immune system should also be analyzed,
particularly B cells, to determine to which degree they
remain repressed over prolonged periods after rituximab
treatment, as suggested already from the early single agent
rituximab study SAKK 35/98 [9] and others [102]. One could
hypothesize that the patient’s T cell response would possibly
be able to eradicate or at least control FL progenitor cells
under such a combination of RIT with rituximab [103], a
hypothesis supported by the observation of long-term CR
after single agent rituximab and single agent RIT.
6. Conclusion
Wewould expect that the combination of RITwith anti-CD20
antibody maintenance in the early treatment of FL has the
potential to be most efficient due to the preservation or/and
stimulation of the patient’s antitumor T cells response. The
addition of anti-PD-1 or anti-CTLA-4 antibodiesmay further
enhance immune responses by reducing inhibitory pathways
and regulatory cells. Indeed, consistent and repeated T
cell stimulation may be achieved by RIT with its capacity
to induce high numbers of CR, combined with rituximab
maintenance capable of maintaining such CR.This approach
may therefore be well suited as novel and readily feasible
perspective towards potential cure of FL.
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